BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22992839)

  • 1. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.
    Beam E; Razonable RR
    Curr Infect Dis Rep; 2012 Dec; 14(6):633-41. PubMed ID: 22992839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus in Solid Organ Transplant Recipients: Clinical Updates, Challenges and Future Directions.
    Razonable RR
    Curr Pharm Des; 2020; 26(28):3497-3506. PubMed ID: 32473617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation.
    Doss KM; Heldman MR; Limaye AP
    Infect Dis Clin North Am; 2023 Nov; ():. PubMed ID: 37989636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in the management of cytomegalovirus infection after solid organ transplantation.
    Eid AJ; Razonable RR
    Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
    Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
    Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
    Kalil AC; Levitsky J; Lyden E; Stoner J; Freifeld AG
    Ann Intern Med; 2005 Dec; 143(12):870-80. PubMed ID: 16365468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
    Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
    Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
    Razonable RR
    World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of cytomegalovirus infection in organ transplant recipients.
    Kusne S; Shapiro R; Fung J
    Transpl Infect Dis; 1999 Sep; 1(3):187-203. PubMed ID: 11428989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.
    Razonable RR; Humar A
    Clin Transplant; 2019 Sep; 33(9):e13512. PubMed ID: 30817026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and Treatment of Cytomegalovirus Infections in Solid Organ Transplant Recipients.
    Koval CE
    Infect Dis Clin North Am; 2018 Sep; 32(3):581-597. PubMed ID: 30146024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.
    Legendre C; Pascual M
    Clin Infect Dis; 2008 Mar; 46(5):732-40. PubMed ID: 18220478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
    Singh N
    Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients.
    Razonable RR
    Am J Health Syst Pharm; 2005 Apr; 62(8 Suppl 1):S7-13. PubMed ID: 15821266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
    Hebart H; Kanz L; Jahn G; Einsele H
    Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.
    Singh N
    J Clin Virol; 2006 Apr; 35(4):474-7. PubMed ID: 16406798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients: a Focus on Prevention.
    Tsai KC; Danziger-Isakov LA; Banach DB
    Curr Infect Dis Rep; 2016 Jan; 18(2):5. PubMed ID: 26743201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients.
    Scott GM; Naing Z; Pavlovic J; Iwasenko JM; Angus P; Jones R; Rawlinson WD
    J Clin Virol; 2011 Aug; 51(4):229-33. PubMed ID: 21641274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy.
    Baillie GM
    Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S10-6. PubMed ID: 16990639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.